Research ArticleOncology
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
Jaeyeon Choi, Wissam Beaino, Ronald J. Fecek, Kellsye P.L. Fabian, Charles M. Laymon, Brenda F. Kurland, Walter J. Storkus and Carolyn J. Anderson
Journal of Nuclear Medicine December 2018, 59 (12) 1843-1849; DOI: https://doi.org/10.2967/jnumed.118.209510
Jaeyeon Choi
1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania
Wissam Beaino
2Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
3VU University Medical Center, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands
Ronald J. Fecek
4Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania
Kellsye P.L. Fabian
5Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
Charles M. Laymon
2Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
Brenda F. Kurland
6Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
Walter J. Storkus
1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania
4Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania
5Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania
Carolyn J. Anderson
1Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania
2Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
7Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; and
8Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 12
December 1, 2018
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
Jaeyeon Choi, Wissam Beaino, Ronald J. Fecek, Kellsye P.L. Fabian, Charles M. Laymon, Brenda F. Kurland, Walter J. Storkus, Carolyn J. Anderson
Journal of Nuclear Medicine Dec 2018, 59 (12) 1843-1849; DOI: 10.2967/jnumed.118.209510
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma
Jaeyeon Choi, Wissam Beaino, Ronald J. Fecek, Kellsye P.L. Fabian, Charles M. Laymon, Brenda F. Kurland, Walter J. Storkus, Carolyn J. Anderson
Journal of Nuclear Medicine Dec 2018, 59 (12) 1843-1849; DOI: 10.2967/jnumed.118.209510
Jump to section
Related Articles
Cited By...
- Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
- Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
- Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
- CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer
- Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
- Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury
- Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer
- Cell Adhesion Molecules in Plasticity and Metastasis
- Combination Strategies to Improve Targeted Radionuclide Therapy